Obesity &amp; Weight Management

Preventive & Routine Care

With comorbid obesity on the rise in type 1 diabetes, researchers examine the potential benefit of semaglutide as an adjunct treatment to insulin.

Should I weigh my patients at every visit?

Alexa Mieses Malchuk, MD, MPH, FAAFP

Preventive & Routine Care

Alexa Mieses Malchuk, MD, MPH, FAAFP, answers.

Should I weigh my patients at every visit?

Alexa Mieses Malchuk, MD, MPH, FAAFP

Alexa Mieses Malchuk, MD, MPH, FAAFP, answers.

Pulmonary Diseases

Zepbound Approval a First for Obstructive Sleep Apnea

Tirzepatide is the first targeted treatment for OSA, addressing obesity’s underlying impact on disease pathophysiology.

Pulmonary Diseases

Zepbound Approval a First for Obstructive Sleep Apnea

Tirzepatide is the first targeted treatment for OSA, addressing obesity’s underlying impact on disease pathophysiology.

Cardiovascular Disorders

Tirzepatide Cuts Heart Failure Events in People with Obesity

Patrice Wendling

SUMMIT trial widens pathway for GLP-1 agonists, experts say. AHA 2024 meeting coverage.

Cardiovascular Disorders

Tirzepatide Cuts Heart Failure Events in People with Obesity

Patrice Wendling

SUMMIT trial widens pathway for GLP-1 agonists, experts say. AHA 2024 meeting coverage.

What’s the best strategy for severe obesity treatment?

Kimberly Gudzune, MD, MPH, FTOS, chief medical officer for the American Board of Obesity Medicine Foundation, discusses how to approach treatment of Class 3 obesity.

What’s the best strategy for severe obesity treatment?

Kimberly Gudzune, MD, MPH, FTOS, chief medical officer for the American Board of Obesity Medicine Foundation, discusses how to approach treatment of Class 3 obesity.

Drug Labeling Gaps for Patients with Obesity Could Lead to Poor Outcomes

What does the FDA intend to do? Plus, how to avoid prolonged drug-drug interactions. An ObesityWeek 2024 highlight.

Drug Labeling Gaps for Patients with Obesity Could Lead to Poor Outcomes

What does the FDA intend to do? Plus, how to avoid prolonged drug-drug interactions. An ObesityWeek 2024 highlight.

GLP-1 Agonists: The Latest Obesity Long-Term Use Data

Oladimeji Ewumi

A comparison of semaglutide, liraglutide, and tirzepatide for weight loss and management. Plus, a preview of what’s in the pipeline.

GLP-1 Agonists: The Latest Obesity Long-Term Use Data

Oladimeji Ewumi

A comparison of semaglutide, liraglutide, and tirzepatide for weight loss and management. Plus, a preview of what’s in the pipeline.

AI in Healthcare

Can AI Predict Weight Loss? Maybe.

Aaron Tallent

New tool estimates potential response to GLP-1 drugs but physicians need to be “very cautious” with their use, say experts.

AI in Healthcare

Can AI Predict Weight Loss? Maybe.

Aaron Tallent

New tool estimates potential response to GLP-1 drugs but physicians need to be “very cautious” with their use, say experts.

Nephrology

Nephrologists “Can No Longer Ignore Obesity”

4 Min Read

New guidance addresses how to effectively address obesity management at different stages of kidney disease.

Nephrology

Nephrologists “Can No Longer Ignore Obesity”

4 Min Read

New guidance addresses how to effectively address obesity management at different stages of kidney disease.

Endocrine Disorders

Study Finds Endothelial IGF-1 Receptor Can Remodel Gut Microbiota

A recent study explored the effect of microbiota regulation on metabolic homeostasis. An ADA meeting highlight.

Endocrine Disorders

Study Finds Endothelial IGF-1 Receptor Can Remodel Gut Microbiota

A recent study explored the effect of microbiota regulation on metabolic homeostasis. An ADA meeting highlight.

Cancer & Blood Disorders

GLP-1 RAs Reduce Obesity-Related Cancer Risk

Marcia Frellick

Glucagon-like peptide-1 receptor agonists reduce obesity-related cancer risk at a similar rate to bariatric surgery, according to new research.

Cancer & Blood Disorders

GLP-1 RAs Reduce Obesity-Related Cancer Risk

Marcia Frellick

Glucagon-like peptide-1 receptor agonists reduce obesity-related cancer risk at a similar rate to bariatric surgery, according to new research.

Medication Management

Which GLP-1 agonist, if any, is right for my patient?

Current evidence and indications for glucose-lowering therapies in diabetes, weight management, and cardiovascular disease.

Medication Management

Which GLP-1 agonist, if any, is right for my patient?